{"schema_version":"secwatch.filing_event.v1","accession":"0001819790-22-000039","form_type":"8-K","ticker":"TARS","cik":"0001819790","company_name":"Tarsus Pharmaceuticals, Inc.","filed_at":"2022-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.319855+00:00","generated_at":"2026-06-22T01:50:30.641590+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Tarsus Q3 net loss $22.5M; NDA accepted for TP-03 with PDUFA Aug 2023","bullets":["Net loss of $22.5M in Q3 2022 vs $15.7M in Q3 2021; R&D expense $10.9M, G&A $12.0M.","Cash and marketable securities $226.6M at Sep 30, 2022; runway into at least 2026.","FDA accepted TP-03 NDA for Demodex blepharitis; PDUFA target action date Aug 25, 2023.","Board changes: Scott Morrison appointed Audit Chair; Chairman Ackermann to depart; CEO Azamian expected to become Chairman.","Expected $30M milestones from LianBio out-license: $10M Dec 2022, $5M Q1 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001819790-22-000039","json":"https://secwatch.observer/filing/0001819790-22-000039.json","markdown":"https://secwatch.observer/filing/0001819790-22-000039.md","text":"https://secwatch.observer/filing/0001819790-22-000039.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1819790/000181979022000039/0001819790-22-000039-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1819790/000181979022000039/tars-20221109.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T01:50:30.641590+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"30f841446cd831f8cd59f9f3dde4ce73100a4b5d","claim":"Tarsus Pharmaceuticals, Inc. reported the third quarter ended September 30, 2022 results: revenue $0, net income $22.5 million.","evidence_excerpt":"to net loss of $15.7 million for the same period in 2021 • Third quarter 2022 license fee and collaboration revenue, as part of the strategic partnership with LianBio, was $0, compared to $1.2 million for the same period in 2021 • Third quarter research and development expenses for 2022 were $10.9 million (inclusive of stock-based compensation of","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1819790/000181979022000039/0001819790-22-000039-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2022"},{"label":"Revenue","value":"$0"},{"label":"Net income","value":"$22.5 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"30f841446cd831f8cd59f9f3dde4ce73100a4b5d","claim":"Tarsus Pharmaceuticals, Inc. reported the third quarter ended September 30, 2022 results: revenue $0, net income $22.5 million.","evidence_excerpt":"Third quarter 2022 license fee and collaboration revenue, as part of the strategic partnership with LianBio, was $0","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1819790/000181979022000039/0001819790-22-000039-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2022"},{"label":"Revenue","value":"$0"},{"label":"Net income","value":"$22.5 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}